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Accepted 2 July 2015Autologous (auto) stem cell transplantation (SCT) and
allogeneic (allo) SCT have been utilized in the treatment of
Hodgkin disease and non-Hodgkin lymphoma. However,
each modality has limitations. Auto SCT has become the
standard transplantation modality in relapsed lymphoma
and is associated with a low incidence of nonrelapse mor-
tality (NRM). Unfortunately, in high-risk lymphomas, such
as early relapsed and/or primary refractory diffuse large
B cell lymphoma (DLBCL) and T cell lymphoma, the relapse
rate after auto SCT is high. Allo SCT has yielded lower
relapse rates because of the graft-versus-lymphoma (GVL)
effect. Traditionally, the beneﬁt of reduced relapse from this
procedure did not translate into an overall survival (OS)
beneﬁt because of high NRM, partly related to myeloa-
blation. Reduced-intensity (RIC)/nonmyeloablative condi-
tioning (NMA) is aimed at exploiting the GVL effect while
reducing the toxicity related to the conditioning regimen.
However, the GVL effect may be insufﬁcient for aggressive
and bulky lymphomas, where disease relapse may precede
the onset of GVL [1]. In these situations, a tandem approach
of cytoreduction from auto SCT and eradication of residual
disease by GVL effect from allo SCT may improve outcomes
over either modality used alone. The rapid resolution of
toxicity after auto SCT followed by RIC/NMA allo SCT may
lower the NRM compared with that after a myeloablative
allo SCT.
Chen et al. report the largest prospective series of tandem
auto SCT followed by allo SCT in high-risk lymphoma in this
issue [2]. Twenty-nine of 42 enrolled patients (69%) were
able to proceed to a RIC allo SCT. The 2-year progression-free
survival (PFS) and OS for patients who were able to undergo
tandem SCT were impressive, at 72% and 89%, respectively.Financial disclosure: See Acknowledgments on page 1534.
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acute graft-versus-host disease rate was low, the 1-year
chronic graft-versus-host disease rate was 37.9%.
Patient selection is key for successful tandem auto SCT
followed by allo SCT. The authors are to be commended for
enrolling patients at high risk of relapse after standard auto
SCT alone. Previously published studies have shown a 3-year
PFS of 23% to 44% in primary refractory and early relapsed
DLBCL (relapse < 12 months from diagnosis) [3,4]. The study
by Chen et al. included patients who relapsed up to
12 months from the end of chemotherapy, double expressing
DLBCL and DLBCL transformed from indolent lymphoma. In
this study, 13 of 18 patients with large B cell morphology
were progression free after auto SCT followed by allo SCT and
of the 5 patients who relapsed, 4 achieved a complete
remission after donor lymphocyte infusion. Remarkably,
none of the 9 patients with double expressing DLBCL expe-
rienced relapse. Although limited by small numbers, the
study demonstrated favorable outcomes in a very high-risk
group of patients.
The tandem approach published by Chen et al. allowed
selection bias such that patients who had disease progres-
sion after auto SCT were not allowed to proceed to allo SCT.
The 2-year PFS and OS for the entire group (n ¼ 42) were
lower than for the patients who underwent both auto SCT
and allo SCT (n¼ 29). Of the 13 patients who did not proceed
to allo SCT after auto SCT, 6 had progressive disease. Because
chemosensitivity is a predictor of good outcome after allo
SCT, this stepwise approach may be a way to prevent the
mortality and morbidity associated with allo SCT in patients
who are at a very high risk of disease relapse and NRM after
allo SCT. The devil’s advocate hypothesis is that myeloa-
blative allo SCT may be able to overcome the chemo-
resistance in a small fraction of these patients; however, the
morbidity and NRM with this approach could be expected to
be higher [5,6]
The study by Chen et al. only included patients who had
HLA-matched donors. Of the 13 patients who did not pro-
ceed to an allo SCT, 2 did not have a HLA-matched donor.
Several recent studies have shown excellent efﬁcacy and
low NRM associated with nonmyeloablative haploidentical
transplantations in relapsed Hodgkin and non-Hodgkin
lymphoma [7,8]. A recent European Society for Blood and
Marrow Transplantation registry analysis showed that
Table 1
Stem cell transplants in lymphoma
Type of SCT Disease Control
from Conditioning
Regimen
NRM Disease
Control
from GVL
Auto SCT Good Low None
RIC/NMA allo SCT Fair Moderate Yes
MAC allo SCT Good High Yes
Tandem auto-allo SCT Good Moderate Yes
MAC indicates myeloablative conditioning.
R.H. Rouce / Biol Blood Marrow Transplant 21 (2015) 1533e15361534relapse incidence was similar after HLA-matched transplants
and alternative donor transplantations. Although NRM
was signiﬁcantly higher in matched unrelated donor and
cord blood transplantations, the NRM for haploidentical and
matched sibling transplantations was similar [9]. Thus,
expanding the donor pool may allow more patients to
beneﬁt from this approach.
In summary, there are 4 different SCTmodalities available
for patients with high-risk lymphoma (Table 1). Careful pa-
tient selection, timing, considerations for disease control
before transplantation and incidence of NRMmay help select
1 modality over another. There is existing literature to sug-
gest excellent disease control and low NRMwhen auto SCT is
used for late relapsed DLBCL (relapse >12 months from
diagnosis) [3,4] and relapsed Hodgkin lymphoma in a posi-
tron emission tomographyenegative complete remission
after salvage therapy [10]. RIC allo SCT has been shown to be
very effective in controlling indolent lymphoma and the
incidence of NRM appears to be higher than auto SCT but
lower than myeloablative allo SCT [11]. Myeloablative allo
SCT has been shown to salvage a small fraction of chemo-
resistant lymphoma, although the beneﬁt could be offset by
high NRM. Finally, the current report from Chen et al. shows
that tandem auto SCT followed by RIC allo SCT can provide
excellent disease control due to cytoreduction followed by
GVL effect. The NRM with this sequential approach appears
to be similar to the NRM observed with RIC/NMA allo SCT
alone.Financial Disclosure: See Acknowledgments on page 1535.
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Accepted 17 July 2015In a study by Davis et al. [1], the impact of persistent
cytomegalovirus (CMV) infection on reconstitution of both
natural killer (NK) and T cell subsets is explored, stratifyingresults based on both CMV seropositivity and graft source.
CMV reactivation was associated with marked increases in
NK cell subsets bearing the CMV adaptive phenotype after
allogeneic hematopoietic stem cell transplantation (HSCT)
irrespective of graft source. The absence of adaptive
(NKG2Cþ/CD57þ) NK cells in CMV-seronegative recipients
who did not reactivate CMV further illustrates that survival of
this memory-like NK subset is dependent on the presence of
CMV antigen and/or chronic CMV infection. Moreover, this
study demonstrates that moremature sibling donor immune
cells impart some protection against reactivation of CMV
seropositive-recipients, even when the sibling donors are
CMV naive. To truly assess the role of NK cells in protection
against rechallenge/reactivation of viruses in the post-HSCT
setting, more clearly deﬁned markers of NK cell memory or
“memory-like function” in models of adaptive immunity is
